PMID- 32321585
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20200910
IS  - 1470-7330 (Electronic)
IS  - 1740-5025 (Print)
IS  - 1470-7330 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Apr 22
TI  - Evaluation of CT-based radiomics signature and nomogram as prognostic markers in 
      patients with laryngeal squamous cell carcinoma.
PG  - 28
LID - 10.1186/s40644-020-00310-5 [doi]
LID - 28
AB  - BACKGROUND: The aim of this study was to evaluate the prognostic value of 
      radiomics signature and nomogram based on contrast-enhanced computed tomography 
      (CT) in patients after surgical resection of laryngeal squamous cell carcinoma 
      (LSCC). METHODS: All patients (n = 136) were divided into the training cohort 
      (n = 96) and validation cohort (n = 40). The LASSO regression method was 
      performed to construct radiomics signature from CT texture features. Then a 
      radiomics nomogram incorporating the radiomics signature and clinicopathologic 
      factors was established to predict overall survival (OS). The validation of 
      nomogram was evaluated by calibration curve, concordance index (C-index) and 
      decision curve. RESULTS: Based on three selected texture features, the radiomics 
      signature showed high C-indexes of 0.782 (95%CI: 0.656-0.909) and 0.752 (95%CI, 
      0.614-0.891) in the two cohorts. The radiomics nomogram had significantly better 
      discrimination capability than cancer staging in the training cohort (C-index, 
      0.817 vs. 0.682; P = 0.009) and validation cohort (C-index, 0.913 vs. 0.699; 
      P = 0.019), as well as a good agreement between predicted and actual survival in 
      calibration curves. Decision curve analysis also suggested improved clinical 
      utility of radiomics nomogram. CONCLUSIONS: Radiomics signature and nomogram 
      showed favorable prediction accuracy for OS, which might facilitate the 
      individualized risk stratification and clinical decision-making in LSCC patients.
FAU - Chen, Linyan
AU  - Chen L
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, and Collaborative Innovation Center, No.37, 
      Guoxue Alley, Chengdu, 610041, People's Republic of China.
FAU - Wang, Haiyang
AU  - Wang H
AD  - Department of Otolaryngology, Head and Neck Surgery, West China Hospital, Sichuan 
      University, Chengdu, People's Republic of China.
FAU - Zeng, Hao
AU  - Zeng H
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, and Collaborative Innovation Center, No.37, 
      Guoxue Alley, Chengdu, 610041, People's Republic of China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, and Collaborative Innovation Center, No.37, 
      Guoxue Alley, Chengdu, 610041, People's Republic of China.
FAU - Ma, Xuelei
AU  - Ma X
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, and Collaborative Innovation Center, No.37, 
      Guoxue Alley, Chengdu, 610041, People's Republic of China. drmaxuelei@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200422
PL  - England
TA  - Cancer Imaging
JT  - Cancer imaging : the official publication of the International Cancer Imaging 
      Society
JID - 101172931
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/*diagnostic imaging/mortality
MH  - Male
MH  - Middle Aged
MH  - *Nomograms
MH  - Prognosis
MH  - Squamous Cell Carcinoma of Head and Neck/*diagnostic imaging/mortality
PMC - PMC7178759
OTO - NOTNLM
OT  - Head and neck cancer
OT  - Laryngeal cancer
OT  - Nomograms
OT  - Prognosis
COIS- The authors declare that they have no competing interests.
EDAT- 2020/04/24 06:00
MHDA- 2020/09/12 06:00
PMCR- 2020/04/22
CRDT- 2020/04/24 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2020/04/22 00:00 [pmc-release]
AID - 10.1186/s40644-020-00310-5 [pii]
AID - 310 [pii]
AID - 10.1186/s40644-020-00310-5 [doi]
PST - epublish
SO  - Cancer Imaging. 2020 Apr 22;20(1):28. doi: 10.1186/s40644-020-00310-5.